Market research
LCTX Lineage Cell Therapeutics, Inc
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 273M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 1.55
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US53566P1093
- Market cap
- 273M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 1.55
About
About Lineage Cell Therapeutics, Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LCTX discussion.
5 years, 4 months ago
Lineage Cell Therapeutics, Inc is currently in a long term uptrend where the price is trading 29.4% above its 200 day moving average.
From a valuation standpoint, the stock is 84.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 202.1.
Lineage Cell Therapeutics, Inc's total revenue sank by 71.4% to $355K since the same quarter in the previous year.
Its net income has increased by 145.3% to $2M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Lineage Cell Therapeutics, Inc gets an overall score of 3/5.